Graduate Program Outcomes

Aggregate Data of Careers 

The aggregated career data of the CMBS program graduates have been deidentified using the safe harbor de-identification method: all names, locations, specific dates beyond the graduation year, and any other identifying information have been removed from the data. These particular analyses are reflective of all graduating trainees dating back to the 2001 graduation year.

Since 2001, ~45% of graduating trainees have gone on to careers in academia, ~35% have accepted positions in industry/pharma, and ~17% have accepted roles in business – primarily venture capital and biotech consulting firms.  This distribution has remained relatively consistent throughout the 20-year period analyzed.  Approximately 40 of the 263 graduated trainees analyzed have gone on to accept positions as professors at academic institutions (27 trainees) or PI-equivalent positions in industry (13 trainees).  This number is likely to continue increasing at a similar rate – in just the last five years (since 2016), a total of 42 trainees have gone on to continue their careers as postdoctoral researchers, with 39 trainees accepting postdoctoral fellowships in academia and another 3 trainees accepting postdoctoral-equivalent positions in industry.

Of the remaining graduated trainees since 2001 that have not gone on to become PIs in academia or industry, 52 of them (~20%) have accepted director or leadership positions throughout academia, pharma, and business.  These include CEO’s of biotech startups, center directors at leading academic research institutions, and named partners at venture capital and biotech consulting firms.

Overall, we have been able to keep track of ~97% of all graduated trainees dating back to 2001.  Nearly 100% of graduates from our program have continued careers in cellular, molecular, and biomedical studies – in associated research, market analysis, drug development, and education.